ATRC
AtriCure·NASDAQ
--
--(--)
--
--(--)
ATRC fundamentals
AtriCure (ATRC) released its earnings on Feb 17, 2026: revenue was 140.50M (YoY +13.05%), beat estimates; EPS was 0.04 (YoY +112.12%), beat estimates.
Revenue / YoY
140.50M
+13.05%
EPS / YoY
0.04
+112.12%
Report date
Feb 17, 2026
ATRC Earnings Call Summary for Q4,2025
- Revenue Beats Expectations: 2025 revenue up 15% to $534M, driven by 33% growth in pain management and 19% in appendage management. 2026 guidance 12-14% growth.
- Clinical Trial Momentum: LeAAPS trial enrollment complete (6,500 patients); BoxX-NoAF trial launched to address post-op Afib. CryoXT device for pain management in amputations being rolled out cautiously.
- Profitability Surge: 2025 adjusted EBITDA $61.8M (+98% YoY). 2026 target $80-82M adjusted EBITDA with modest gross margin expansion.
- Competitive Resilience: Maintained leadership despite competitor entry, with 24% Q4 growth in open appendage management. U.S. open ablation revenue up 17% YoY.
- Key Risk: U.K. sales decline (-$3M Q4) due to NHS funding cuts, but international growth (17.5% ex-U.K.) offsets.
EPS
Actual | -0.42 | -0.2 | -0.11 | -0.42 | -0.38 | -0.36 | 2.11 | -0.3 | -0.33 | -0.32 | -0.27 | -0.09 | -0.14 | -0.11 | -0.2 | -0.21 | -0.28 | -0.17 | -0.17 | -0.33 | -0.14 | -0.13 | -0.01 | 0.04 | ||||||||||
Forecast | -0.4143 | -0.5786 | -0.34 | -0.28 | -0.3864 | -0.335 | -0.3256 | -0.29 | -0.32 | -0.2931 | -0.2568 | -0.1761 | -0.3101 | -0.2962 | -0.3045 | -0.2248 | -0.2294 | -0.1681 | -0.1949 | -0.2023 | -0.225 | -0.1671 | -0.1119 | -0.0868 | ||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1.38% | +65.43% | +67.65% | -50.00% | +1.66% | -7.46% | +748.03% | -3.45% | -3.13% | -9.18% | -5.14% | +48.89% | +54.85% | +62.86% | +34.32% | +6.58% | -22.06% | -1.13% | +12.78% | -63.12% | +37.78% | +22.20% | +91.06% | +146.08% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 53.23M | 40.82M | 54.76M | 57.73M | 59.27M | 71.38M | 70.46M | 73.22M | 74.58M | 84.53M | 83.25M | 88.03M | 93.49M | 100.92M | 98.29M | 106.54M | 108.85M | 116.27M | 115.91M | 124.28M | 123.62M | 136.14M | 134.27M | 140.50M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 55.50M | 35.94M | 49.37M | 58.02M | 56.06M | 61.09M | 68.59M | 72.66M | 71.17M | 79.60M | 81.79M | 87.78M | 88.48M | 97.55M | 96.65M | 103.68M | 106.86M | 116.24M | 112.23M | 121.25M | 122.90M | 130.18M | 131.26M | 139.71M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4.10% | +13.58% | +10.91% | -0.50% | +5.73% | +16.85% | +2.72% | +0.77% | +4.79% | +6.19% | +1.78% | +0.28% | +5.66% | +3.45% | +1.70% | +2.76% | +1.87% | +0.03% | +3.28% | +2.50% | +0.59% | +4.58% | +2.29% | +0.56% |
Earnings Call
You can ask Aime
What is AtriCure's latest dividend and current dividend yield?What guidance did AtriCure's management provide for the next earnings period?What were the key takeaways from AtriCure’s earnings call?What does AtriCure do and what are its main business segments?What is the revenue and EPS growth rate for AtriCure year over year?What were the key takeaways from AtriCure's earnings call?What is AtriCure's gross profit margin?Did AtriCure beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
